Teva Can Preserve $5-a-Share Earnings Goal With Mylan: Real M&A
Inside a Possible Teva, Mylan Merger
This article is for subscribers only.
There’s no better deal for Teva Pharmaceutical Industries Ltd. right now than Mylan NV.
Teva is evaluating a purchase of $34 billion Mylan in what would be the biggest pharmaceutical acquisition so far this year. It comes after months of analysts saying Teva should consider such an acquisition to help offset the drop in revenue and profit that’s expected after generic copies of its top medicine, Copaxone, hit the market. Just Thursday, a team of two drugmakers said they won U.S. approval to market their generic version. Mylan is also seeking approval to sell generic Copaxone.